The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
T cell costimulatory receptor CD28 is a primary target for PD-1–mediated inhibition
Open accessPublished version of a preprint
Abstract
Immunotherapeutic PD-1–targeted therapies require CD28 to promote cancer cell killing.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Ligation of PD-1 with its ligands programmed death-ligand 1 or 2 (PD-L1 or PD-L2) induces tyrosine phosphorylation of the PD-1 cytoplasmic domain by phosphorylating kinase Lck and subsequent recruitment of cytosolic tyrosine phosphatase SHP-2 and PD-1-associated SHP-2 preferentially dephosphorylates CD28 and suppresses CD28 costimulatory signaling leading to restrained effector T cell function (49”
From mRNA vaccine with unmodified uridine induces robust type I interferon-dependent anti-tumor immunity in a melanoma model (2022) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Overcoming such checkpoints through the use of therapeutic antibodies targeting the CTLA-4, PD-1, or PD-L1 cell-surface receptors was shown to be instrumental in promoting anti-tumor T cell responses in mice and in cancer patients”
From LXR/ApoE Activation Restricts Innate Immune Suppression in Cancer (2018) · cites this paper as Hui et al., 2017
Experimental — accuracy not yet measuredIn the citing paper
“SHP2 also has effects on parallel pathways (e.g., JAK/STAT signaling) and is implicated as an effector of inhibitory signaling by PD-1 and some other immune checkpoint receptors (Hui et al., 2017; Peled et al., 2018; Yokosuka et al., 2012).”
From SHP2 inhibition diminishes KRASG12C cycling and promotes tumor microenvironment remodeling (2021) · cites this paper as Hui et al., 2017
In the citing paper
“Among these, CD28 has recently been found to be the primary target (45).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [45]
In the citing paper
“The requirement for both T cell co-stimulation and IL-12 to achieve maximal IFN-γ response likely reflected the need of CD28 to rescue exhausted CD8+ T cells, and possibly also the role of PD-1 in limiting CD28-mediated co-stimulation (Kamphorst et al., 2017; Hui et al., 2017).”
From Successful Anti-PD-1 Cancer Immunotherapy Requires T Cell-Dendritic Cell Crosstalk Involving the Cytokines IFN-γ and IL-12 (2018) · cites this paper as Hui et al., 2017
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citationPD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Self-citationTumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Flagged first, then by citations
Cited by
Sorted by citations
Items 901–1,000 of 1,002
Wang, Y., He, S., Calendo, G., Bui, T., Tian, Y., Lee, C. Y., Zhou, Y., Zhao, X., Abraham, C., Mo, W., et al. (2023) · Blood · doi:10.1182/blood.2023021126 · Cited by 15
Holling, G. A., Chavel, C. A., Sharda, A. P., Lieberman, M. M., James, C. M., Lightman, S. M., Tong, J. H., Qiao, G., Emmons, T. R., Giridharan, T., et al. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01124-2 · Cited by 16
Xin, X., Zhu, X., Yang, Y., Wang, N., Wang, J., Xu, J., Wei, J., Huang, L., Zheng, M., Xiao, Y. Q., et al. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00940-y · Cited by 16
Li, D., Lan, X., Xu, L., Zhou, S., Luo, H., Zhang, X., Yu, W., Yang, Y., & Fang, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1552010 · Cited by 17
SAP interacts with CD28 to inhibit PD-1 signaling in T lymphocytes
Sandigursky, S., Philips, M. R., & Mor, A. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108485 · Cited by 16
Biomarkers for immune checkpoint therapy targeting programmed death 1 and programmed death ligand 1
Fan, J., Shen, X., Wang, Y., Zhou, H., Liu, G., Li, Y., & Xu, Z. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110621 · Cited by 15
Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
Sawaisorn, P., Atjanasuppat, K., Anurathapan, U., Chutipongtanate, S., & Hongeng, S. (2020) · Vaccines · doi:10.3390/vaccines8040753 · Cited by 14
Rallis, K. S., Hillyar, C., Sideris, M. C., & DAVIES, J. K. (2021) · Anticancer Research · doi:10.21873/anticanres.14870 · Cited by 16
Okada, N., Sugiyama, K., Shichi, S., Shirai, Y., Goto, K., Sakane, F., Kitamura, H., & Taketomi, A. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03041-z · Cited by 15
Mélique, S., Yang, C., & Lesourne, R. (2022) · Biomedical Journal · doi:10.1016/j.bj.2022.03.008 · Cited by 16
Antigen self-presenting nanovaccine for cancer immunotherapy
Liang, X., Cheng, H., Liu, C., & Liu, G. (2022) · 中国科学通报：英文版 · doi:10.1016/j.scib.2022.07.018 · Cited by 15
On the Biology and Therapeutic Modulation of Macrophages and Dendritic Cells in Cancer
Park, M. D., Belabed, M., Chen, S. T., Hamon, P., Hegde, S., Mattiuz, R., Marron, T. U., & Mérad, M. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061521-085949 · Cited by 15
Takeda, K., Kitaura, K., Suzuki, R., Owada, Y., Muto, S., Okabe, N., Hasegawa, T., Osugi, J., Hoshino, M., Tsunoda, T., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2152-x · Cited by 16
Biswas, K. H., Zhongwen, C., Dubey, A. K., Oh, D., & Groves, J. T. (2018) · Advanced Biosystems · doi:10.1002/adbi.201800015 · Cited by 15
Greene, E., Finak, G., D’Amico, L. A., Bhardwaj, N., Church, C. D., Morishima, C., Ramchurren, N., Taube, J. M., Nghiem, P., Cheever, M. A., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/702118 · Cited by 14
Seethapathy, H., Mistry, K., & Sise, M. E. (2023) · Immunological Reviews · doi:10.1111/imr.13243 · Cited by 15
Kang, D., Wang, Y., Lin, Y., Ma, W. W., Morgensztern, D., Leventakos, K., Bi, C., Ding, Y., Xiong, J., Yan, M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-3691 · Cited by 17
Post‐transcriptional control of T‐cell cytokine production: Implications for cancer therapy
Heeren, J. J. F. (2021) · Immunology · doi:10.1111/imm.13339 · Cited by 14
Quantitative contributions of TNF receptor superfamily members to CD8+ T‐cell responses
Nguyen, J., Pettmann, J., Krüger, P., & Dushek, O. (2021) · Molecular Systems Biology · doi:10.15252/msb.202110560 · Cited by 14
ATRA promotes PD-L1 expression to control gastric cancer immune surveillance
Ma, Z., Ding, Y.-L., Jing, J., Du, L., Zhang, X.-Y., Liu, H., & He, P. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174822 · Cited by 14
Zeke, A., Takács, T., Sok, P., Németh, K., Kirsch, K., Egri, P., Póti, Á., Bento, I., Tusnády, G., & Reményi, A. (2022) · Nature Communications · doi:10.1038/s41467-022-32918-5 · Cited by 14
Extracellular vesicle-based checkpoint regulation and immune state in cancer
Mortezaee, K., & Majidpoor, J. (2022) · Medical Oncology · doi:10.1007/s12032-022-01837-2 · Cited by 14
Concomitant deletion of Ptpn6 and Ptpn11 in T cells fails to improve anticancer responses
Ventura, P., Gakovic, M., Fischer, B. A., Spinelli, L., Rota, G., Pathak, S., Khameneh, H. J., Zenobi, A., Thomson, S., Birchmeier, W., et al. (2022) · EMBO Reports · doi:10.15252/embr.202255399 · Cited by 14
The Changing Landscape of Immunotherapy for Advanced Renal Cancer
Kashima, S., & Braun, D. A. (2023) · Urologic Clinics of North America · doi:10.1016/j.ucl.2023.01.012 · Cited by 14
Tian, W., Qin, G., Jia, M., Li, W., Cai, W., Wang, H., Zhao, Y., Bao, X., Wei, W., Zhang, Y., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1198551 · Cited by 16
Sharon, S., Daher-Ghanem, N., Zaid, D., Gough, M. J., & Kravchenko‐Balasha, N. (2023) · Frontiers in Oral Health · doi:10.3389/froh.2023.1180869 · Cited by 16
Dougan, M. L. (2023) · Immunological Reviews · doi:10.1111/imr.13239 · Cited by 15
Abdelbary, M. A., & Nolz, J. C. (2023) · Immunometabolism · doi:10.1097/in9.0000000000000035 · Cited by 15
Wang, L., Matsumoto, M., Akahori, Y., Seo, N., Shirakura, K., Kato, T., Katsumoto, Y., Miyahara, Y., & Shiku, H. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.018 · Cited by 18
Dahlquist, K. J. V., Huggins, M. A., Yousefzadeh, M. J., Soto-Palma, C., Cholensky, S. H., Pierson, M. J., Smith, D. M., Hamilton, S. E., & Camell, C. D. (2024) · Nature Aging · doi:10.1038/s43587-024-00620-4 · Cited by 17
Peng, P., Chavel, C. A., Liu, W., Carlson, L. M., Cao, S., Utley, A. T., Olejniczak, S. H., & Lee, K. P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114445 · Cited by 16
Nanoparticles targeting immune checkpoint protein VISTA induce potent antitumor immunity
Moon, T. J., Ta, H. M., Bhalotia, A., Paulsen, K. E., Hutchinson, D. W., Arkema, G. M., Choi, A. S., Haynie, M. G., Ogunnaike, L., Dever, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008977 · Cited by 16
Ploch, W., Sadowski, K. A., Olejarz, W., & Basak, G. W. (2024) · Cancers · doi:10.3390/cancers16193339 · Cited by 13
Sanchez, J. C., Pierpont, T. M., Argueta-Zamora, D., Wilson, K. F., August, A., & Cerione, R. A. (2024) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2024.108143 · Cited by 16
Immune involvement of the contralateral hemisphere in a glioblastoma mouse model
Crommentuijn, M. H. W., Schetters, S. T. T., Dusoswa, S. A., Kruijssen, L. J. W., García-Vallejo, J. J., & van Kooyk, Y. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000323 · Cited by 15
Tanaka, I., & Morise, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010245 · Cited by 14
JAML immunotherapy targets recently activated tumor-infiltrating CD8+ T cells
Eschweiler, S., Wang, A., Ramírez-Suástegui, C., Witzleben, A. V., Li, Y., Chee, S., Simon, H. A., Mondal, M., Ellis, M. J., Thomas, G. J., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112040 · Cited by 13
PD-1 limits differentiation and plasticity of Tc17 cells
Arra, A., Lingel, H., Pierau, M., & Brunner-Weinzierl, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1104730 · Cited by 12
Geometric optimisation of electrohydrodynamic fluid flows for enhanced biosensing
Wuethrich, A., Howard, C. B., & Trau, M. (2017) · Microchemical Journal · doi:10.1016/j.microc.2017.10.012 · Cited by 14
Mitchell, L., Yagiz, K., Hofacre, A., Viaud, S., Munday, A. W., Espinoza, F. L., Mendoza, D., Rodriguez-Aguirre, M. E., Bergqvist, S., Haghighi, A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26785 · Cited by 14
Understanding T cell signaling using membrane reconstitution
Hui, E. (2019) · Immunological Reviews · doi:10.1111/imr.12767 · Cited by 14
Self-citationLi, W., Zhan, M., Quan, Y., Wang, H., Hua, S., Li, Y., Zhang, J., Lu, L., & Cui, M. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106227 · Cited by 14
Human CXCR5 + PD‐1 + CD8 T cells in healthy individuals and patients with hematologic malignancies
Hofland, T., Martens, A. W. J., van Bruggen, J. A. C., de Boer, R., Schetters, S. T. T., Remmerswaal, E. B. M., Bemelman, F. J., Levin, M., Bins, A. D., Eldering, E., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202048761 · Cited by 15
Dölz, M., Hasiuk, M., Gagnon, J. D., Kornete, M., Marone, R., Bantug, G. R., Kageyama, R., Hess, C., Ansel, K. M., Seyres, D., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105372 · Cited by 14
Unlocking the mystery of the PD-1/PD-L1 axis: beyond the checkpoint hype
Desimpel, P.-H., Petit, P.-F., den Eynde, B. J. V., & Zhu, J. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1708873 · Cited by 16
Self-citationQin, J., Zhang, M., Guan, Y., Guo, X., Li, Z., Rankl, C., & Tang, J. (2021) · Analytica Chimica Acta · doi:10.1016/j.aca.2021.339281 · Cited by 11
Allosteric inhibition of SHP2 rescues functional T-cell abnormalities in SAP deficiency
Panchal, N., Houghton, B. C., Vassalou, E., Thrasher, A. J., & Booth, C. (2022) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2022.06.021 · Cited by 13
Li, Q., Wei, S., Li, Y., Wu, F., Qin, X., Li, Z., Li, J., & Chen, C. (2023) · Inflammation Research · doi:10.1007/s00011-023-01703-5 · Cited by 13
Donini, C., Galvagno, F., Rotolo, R., Massa, A., Merlini, A., Scagliotti, G. V., Novello, S., Bironzo, P., Leuci, V., & Sangiolo, D. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02363-2 · Cited by 13
Kinoshita, S., Ishii, M., Ando, J., Kimura, T., Yamaguchi, T., Harada, S., Takahashi, F., Nakashima, K., Nakazawa, Y., Yamazaki, S., et al. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0259 · Cited by 14
Skadborg, S. K., Maarup, S. B., Draghi, A., Borch, A., Hendriksen, S., Mundt, F., Pedersen, V., Mann, M., Christensen, I. J., Skjøth-Ramussen, J., et al. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0959 · Cited by 16
Generation of antitumor chimeric antigen receptors incorporating T cell signaling motifs
Balagopalan, L., Moreno, T., Qin, H., Angeles, B., Kondo, T., Yi, J., McIntire, K. M., Alvinez, N., Pallikkuth, S., Lee, M. E., et al. (2024) · Science Signaling · doi:10.1126/scisignal.adp8569 · Cited by 14
PD-L1 restrains PD-1+Nrp1lo Treg cells to suppress inflammation-driven colorectal tumorigenesis
Poschel, D. B., Klement, J. D., Merting, A. D., Lu, C., Zhao, Y., Yang, D., Xiao, W. L., Zhu, H., Rajeshwari, P., Toscano, M. L., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114819 · Cited by 14
Zhao, Y., Qiu, W., Liu, J., Yuan, X., Mao, W., Yin, J., Peng, B., Liu, W., Han, S. H., & He, X. (2020) · The FASEB Journal · doi:10.1096/fj.202000861rr · Cited by 12
Non-redundant activity of GSK-3α and GSK-3β in T cell-mediated tumor rejection
Steele, L. P., Mannion, A. J., Shaw, G. C., MacLennan, K., Cook, G. P., Rudd, C. E., & Taylor, A. (2021) · iScience · doi:10.1016/j.isci.2021.102555 · Cited by 12
Capitani, N., Patrussi, L., & Baldari, C. T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222011221 · Cited by 15
Qin, Z., Liu, K., Xu, X., Li, T., Ge, Y., Wu, B., Xing, C., & Mao, H. (2022) · Future Oncology · doi:10.2217/fon-2021-1004 · Cited by 13
Cammann, C., Israel, N., Frentzel, S., Jeron, A., Topfstedt, E., Schüler, T., Simeoni, L., Zenker, M., Fehling, H. J., Schraven, B. L., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.958616 · Cited by 13
Jiang, B., Wang, S., Song, G., Jiang, Q., Fan, M., Fang, C., Li, X., Soh, C. L., Manes, T. D., Cheru, N. T., et al. (2023) · Science Signaling · doi:10.1126/scisignal.abo3406 · Cited by 13
Human regulatory T cells (Treg) and their response to cancer
Whiteside, T. L. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1634471 · Cited by 14
Costimulation, a surprising connection for immunotherapy
Clouthier, D., & Ohashi, P. S. (2017) · Science · doi:10.1126/science.aan1467 · Cited by 13
Shi, H., Xiao, M., Li, Y., Liu, X., Na, J., Liang, C., Hua, J., Meng, Q., Wei, M., Wang, W., et al. (2025) · Theranostics · doi:10.7150/thno.112633 · Cited by 12
Targeting IL-34/MCSF-1R Axis in Colon Cancer
Monteleone, G., Maresca, C., Colella, M., Pacifico, T., Congiu, D., Troncone, E., & Marafini, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.917955 · Cited by 13
Reprograming immune microenvironment modulates CD47 cancer stem cells in hepatocellular carcinoma
El-Fattah, E. E. A., & Selim, H. M. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109475 · Cited by 13
White, D., Cote-Martin, A., Bleck, M., Garaffa, N., Shaaban, A., Wu, H. L., Liu, D., Young, D. S., Scheer, J. K., Lorenz, I. C., et al. (2023) · Molecular Immunology · doi:10.1016/j.molimm.2023.02.007 · Cited by 12
Targeting SHP2 Signaling in Lung Cancer
Imbody, D. J., Arce-Ruiz, K. M., Solanki, H. S., Haura, E. B., & Pellini, B. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.08.009 · Cited by 12
Mellergaard, M., Skovbakke, S. L., Jepsen, S. D., Panagiotopoulou, N., Hansen, A. B. R., Tian, W., Lund, A., Høgh, R. I., Møller, S. H., Guérillot, R., et al. (2023) · mBio · doi:10.1128/mbio.01349-23 · Cited by 12
Protein tyrosine phosphatases as emerging targets for cancer immunotherapy
Qu, Z., Dong, J., & Zhang, Z. (2023) · British Journal of Pharmacology · doi:10.1111/bph.16304 · Cited by 12
Cheng, C., Zha, Q., Sun, L., Cui, T., Guo, X., Xing, C., Chen, Z., Ji, C., Liang, S., Tao, S., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02120-8 · Cited by 14
Upadhyay, S., Talagayev, V., Cho, S., Wolber, G., & Gabr, M. T. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118194 · Cited by 12
To do or not to do: A concise update of current clinical controversies in immune checkpoint blockade
Chung, C. (2018) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155218786365 · Cited by 12
Design of novel SHP2 inhibitors using Topomer CoMFA, HQSAR analysis, and molecular docking
Tong, J., Luo, D., Zhang, X., & Bian, S. (2020) · Structural Chemistry · doi:10.1007/s11224-020-01677-8 · Cited by 12
Sapski, S., Beha, N., Kontermann, R. E., & Müller, D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1361594 · Cited by 13
The Influence of Molecular Reach and Diffusivity on the Efficacy of Membrane-Confined Reactions
Zhang, Y., Clemens, L., Goyette, J., Allard, J. F., Dushek, O., & Isaacson, S. A. (2019) · Biophysical Journal · doi:10.1016/j.bpj.2019.08.023 · Cited by 12
Stimulatory and Inhibitory Co-signals in Autoimmunity
Okazaki, T., & Okazaki, I. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-981-32-9717-3_8 · Cited by 12
Novel Immunomodulatory Proteins Generated via Directed Evolution of Variant IgSF Domains
Levin, S. D., Evans, L. S., Bort, S. J., Rickel, E., Lewis, K. E., Wu, R. P., Hoover, J., MacNeil, S., La, D., Wolfson, M. F., et al. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03086 · Cited by 12
Engineering CD4+ T Cells to Enhance Cancer Immunity
Sillito, F. E., Holler, A., & Stauss, H. J. (2020) · Cells · doi:10.3390/cells9071721 · Cited by 12
Prognostic and clinicopathological value of PD-L2 in lung cancer: A meta-analysis
Lin, X., Lin, K., Lin, C., Liu, T., Ba, M., Tang, Y., Wang, J.-L., Zhou, L., Wang, J., & Xiao, C. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107280 · Cited by 12
Liu, J. J., Xin, B., Du, L., Chen, L., Long, Y., & Feng, G. (2023) · Hepatology · doi:10.1002/hep.32555 · Cited by 11
Majocchi, S., Lloveras, P., Nouveau, L., Legrand, M., Viandier, A., Malinge, P., Charreton, M., Raymond, C., Pace, E. A., Millard, B. L., et al. (2025) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0298 · Cited by 12
Zhang, H., Gong, L., Li, Y., Xian, C., Ma, Z., Wang, X., & Xia, R. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03809-8 · Cited by 13
Tan, J. Y., Low, M. H., Chen, Y., & Lim, F. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23136931 · Cited by 12
Mechanism of exosomes in the tumor microenvironment in the abscopal effect (Review)
Kuang, G., Wang, Z., Luo, C., Luo, J., & Wang, J. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5450 · Cited by 11
Edner, N. M., Ntavli, E., Petersone, L., Wang, C. J., Fabri, A., Kogimtzis, A., Ovcinnikovs, V., Ross, E. M., Heuts, F. W. H., Elfaki, Y., et al. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad001 · Cited by 13
What is the optimal duration, dose and frequency for anti-PD1 therapy of non-small cell lung cancer?
Kuah, C. Y., Monfries, R., Quartagno, M., Seckl, M. J., & Ghorani, E. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231210271 · Cited by 12
Complex Roles of PTPN11/SHP2 in Carcinogenesis and Prospect of Targeting SHP2 in Cancer Therapy
Scheiter, A., Lu, L., Gao, L. H., & Feng, G. (2023) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-062722-013740 · Cited by 13
Cheng, H., & Zheng, Y. (2024) · PeerJ · doi:10.7717/peerj.16825 · Cited by 13
Mélique, S., Vadel, A., Rouquié, N., Yang, C., Bories, C., Cotineau, C., Saoudi, A., Fazilleau, N., & Lesourne, R. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2318773121 · Cited by 12
Ferroptosis in Cancer: A new perspective on T cells
Lai, Y., Huang, C., Wu, J., Yang, K., & Yang, L. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113539 · Cited by 13
Montagner, A., Arleo, A., Suzzi, F., D’Assoro, A. B., Piscaglia, F., Gramantieri, L., & Giovannini, C. (2024) · Biomolecules · doi:10.3390/biom14121581 · Cited by 11
Physical chemistry in a single live cell: confocal microscopy
Amin, M. A., Nandi, S., Mondal, P., Mahata, T., Ghosh, S., & Bhattacharyya, K. (2017) · Physical Chemistry Chemical Physics · doi:10.1039/c7cp02228j · Cited by 11
Metabolic regulation of the HBV-specific T cell function
Barili, V., Boni, C., Rossi, M., Vecchi, A. L., Zecca, A., Penna, A., Missale, G., Ferrari, C. I., & Fisicaro, P. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104989 · Cited by 12
Wang, Q., Zhao, W., Fu, X., & Zheng, Q. (2020) · Frontiers in Chemistry · doi:10.3389/fchem.2020.597495 · Cited by 11
Expression regulation and function of PD-1 and PD-L1 in T lymphoma cells
Liu, M. Y., Klement, J. D., Poole, C. J., van Riggelen, J., & Liu, K. (2021) · Cellular Immunology · doi:10.1016/j.cellimm.2021.104397 · Cited by 11
Immuno-onco-metabolism and Therapeutic Resistance
Mir, M. A., Aisha, S., Nisar, S., Qayoom, H., & Mehraj, U. (2022) · Springer eBooks · doi:10.1007/978-981-16-6226-3_3 · Cited by 11
Oliveira-Scussel, A. C. D. M., Ferreira, P. T. M., Resende, R. D. S., Ratkevicius, C. M. A., Gomes, A. D. O., Paschoini, M. C., Vito, F. B. D., Farnesi-de-Assunção, T. S., da Silva, M. V., Mineo, J. R., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.925762 · Cited by 11
Feng, F., Liu, Y., Liu, G., Zhu, P., Zhu, M., Zhang, H., Lu, X., Liu, J., Luo, X., & Yu, Y. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01442 · Cited by 11
Engineering Platforms for T Cell Modulation
Hickey, J. W., Kosmides, A. K., & Schneck, J. P. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.06.003 · Cited by 11
Sverdlov, E. D. (2018) · BioEssays · doi:10.1002/bies.201800079 · Cited by 11
Garg†, S. K., Welsh, E. A., Fang, B., Hernandez, Y., Rose, T. A., Gray, J. E., Koomen, J. M., Berglund, A., Mulé, J. J., & Markowitz, J. (2020) · Cancers · doi:10.3390/cancers12123515 · Cited by 11
Metadata
- Authors
- Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, M. J., Wallweber, H. A., Sasmal, D. K., Huang, J., Kim, J. M., Mellman, I., & Vale, R. D.
- Affiliations
- Howard Hughes Medical Institute (US)
- Genentech (US)
- University of Chicago (US)
- Corresponding author
- Mellman, Ira
- Vale, Ronald D.
- ORCID
- Venue
- Science
- Published
- 2017-03-31
- Volume
- 355
- Issue
- 6332
- Pages
- 1428-1433
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC6286077
- OpenAlex
- W2592133876
- Cited by
- 1,689
- References
- 68
- Citations by year
- 2026: 121 · 2025: 158 · 2024: 201 · 2023: 203 · 2022: 193 · 2021: 218 · 2020: 224 · 2019: 159 · 2018: 143 · 2017: 63
- FWCI
- 70.99
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- Science (publishedVersion)
- bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- MPG.PuRe (Max Planck Society) (submittedVersion, other-oa)
- Funders
- Chicago Biomedical Consortium
- NIH (R21AI120010, R00AI106941)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Keywords
- PD-1, CD28, PD-L1, T cell costimulation, T cell receptor signaling, SHP2, receptor dephosphorylation, T cell activation, anti-PD-1 therapy, cancer immunotherapy
- MeSH terms
- Animals, Humans, Immunotherapy, Lymphocyte Activation, Mice, Inbred C57BL, Neoplasms, Phosphorylation, T-Lymphocytes, CD28 Antigens, Jurkat Cells, Mice, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
